acute heart failure
Conditions
Interventions
Initial treatments (intravenous administration) is a randomized (1:1) to carperitide and nitrate.
Nitrate
Sponsors
National Cerebral and Cardiovascular Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) over 20 years 2) NYHA functional class: 2-3 3) Systolic blood pressure: greater than or equal to 120mmHg 4) written informed consent
Exclusion criteria
Exclusion criteria: 1) Patients with acute myocaridal infarction and unstable angina, which occurs within 3 months 2) Patients with valvular heart disease which requires surgical treatments 3) Patients with persistent fever greater than or equal to 38 degree celcius 4) Patients with cancer 5) Patients who received surgery or significant trauma within 6 months 6) Patients with inflamative disease 7) Patients who requires ventricular assist device 8) Patients who receive dialysis 9) Patients with severe dehydration 10) Patients considered ineligible to participate in this study by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Frequency of composite cardiovascular event after the initiation of the treatments | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Changes in NYHA (before, 3hours and 2days after the initiation of the treatments) 2) Echocardiographical changes (LVDd, LVDs, LVEF, E/A, VTI) (before and 14 days after the the initiation of the treatments) 3) Changes in plasma BNP levels (before and 14 days after the the initiation of the treatments) 4) Changes in systolic blood pressure during protocol 5) Changes in estimated GFR during protocol | — |
Countries
Japan
Contacts
Public ContactHiroyuki Takahama
National Cerebral and Cardiovascular Center Department of Cardiovascular Medicine
Outcome results
None listed